1. Home
  2. VTVT vs EDF Comparison

VTVT vs EDF Comparison

Compare VTVT & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

HOLD

Current Price

$42.70

Market Cap

143.7M

Sector

Health Care

ML Signal

HOLD

Logo Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

EDF

Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

HOLD

Current Price

$4.90

Market Cap

160.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTVT
EDF
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
143.7M
160.5M
IPO Year
2015
2010

Fundamental Metrics

Financial Performance
Metric
VTVT
EDF
Price
$42.70
$4.90
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$53.00
N/A
AVG Volume (30 Days)
48.6K
235.9K
Earning Date
05-14-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.00
$4.14
52 Week High
$44.00
$5.34

Technical Indicators

Market Signals
Indicator
VTVT
EDF
Relative Strength Index (RSI) 61.25 41.84
Support Level $31.93 $4.83
Resistance Level $41.88 $5.03
Average True Range (ATR) 3.13 0.10
MACD 0.48 -0.02
Stochastic Oscillator 82.60 32.02

Price Performance

Historical Comparison
VTVT
EDF

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.

About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.

Share on Social Networks: